Brentuximab vedotin demonstrated manageable toxic effects and elicited objective responses in a majority of patients with relapsed or refractory CD30‐positive lymphomas during the initial phase I trial (NCT00430846).330. Here, TNFRSF8 is linked to lymphoma.